Sign in Register Submit Manuscript

Damray Home

Location: Home >> Comparison of Coagulation Profile in Type 2 Diabetes Mellitus Patients at Durame General Hospital, South East Ethiopia: Comparative Cross-sectional Study

  • donwnload article

    Download Article

  • donwnload article

    Share Article


Comparison of Coagulation Profile in Type 2 Diabetes Mellitus Patients at Durame General Hospital, South East Ethiopia: Comparative Cross-sectional Study

Yazal Abay1,*, Melatwork Tibebu2, Zemenu Tamir2

1Department of Medical Laboratory Sciences, College of Health Sciences, Wolkite Uni-versity, Ethiopia.

2Zemenu Tamir, Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

*Corresponding author: Yazal Abay

Published: 10 July 2024 How to cite this paper


Background: Diabetes mellitus is related to disturbances of hemostasis that could subsidize the occurrence of thrombogenic complications. Diabetic patients are exposed to thrombosis, which arises from cardiovascular events, the rest from cerebrovascular events along with peripheral vascular complications, and these are correlated with diabetes results for most of its morbidity, and mortality. The current study was carried out to determine the coagulation profiles of type 2 diabetes mellitus patients in comparison with apparently healthy controls. Methods: A comparative cross-sectional study was carried out at Durame General Hospital from June 2023 to January 2024. Socio-demographic and clinical data were collected using questionnaires and checklists. Platelet parameters were determined from EDTA anticoagulated venous blood using an Adevia560 hematological analyzer, whereas coagulation analysis was done using an ARES LiNEAR coagulation analyzer from citrated plasma. Kolmogorov-Smirnov tests were used to check distribution, and data was analyzed using SPSS version 26 software. An unpaired t-test was used to compare the mean between groups and the Kruskal Wallis test for the comparison of different categories in groups. Statistical significance was designed at (P< 0.05). Results: There was a significant shortening of prothrombine time (PT) (12.9±1.5, vs 13.5±1.3), (p=0.02), and International normalized ration (INR) (1.08±0.16, vs 1.13±0.17), (p= 0.04) and significant increase of platelet count, MPV (12.1±1.9, vs 10.9±1.5, p<0.001), PDW (16.7±2.1, vs 15.5±1.8, p<0.001 between diabetics compared to controls respectively. Platelet count showed a weak positive correlation with fasting blood glucose level (r=0.26, p=0.02). Conclusion: The present study revealed reduced values of PT, and INR, and increased values of Plt count, MPV, and PDW among type 2 diabetic patients compared to apparently healthy controls. Thus, the finding is suggestive of hypercoagulable tendencies of diabetic patients compared to controls.

KEYWORDS: Type 2 Diabetes Mellitus, coagulation profiles, platelet indices, hypercoagulable state, comparative study, Ethiopia


[1] Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J., 2012, 27(4):269-73.

[2] Sicree R, Shaw J, Zimmet P. Prevalence and projections. Diabetes Atlas., 2006, 3:16-104.

[3] DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers, 2015, 1:15019.

[4] Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Research and Clinical Practice, 2019, 157:107843.

[5] Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endo-crinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocrine Practice, 2013, 19:1-48.

[6] Ruszkowska-Ciastek B, Sokup A, Wernik T, Rhone P, Goralczyk K, Bielawski K, et al. Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2. J Zhejiang Univ Sci B., 2015, 16(9):788-95.

[7] Dayer MR, Mard-Soltani M, Dayer MS, Alavi SMR. Causality relationships between coagulation factors in type 2 diabetes mellitus: path analysis approach. Medical Journal of the Islamic Republic of Iran, 2014, 28:59.

[8] Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth, 2014, 58(5):515-23.

[9] Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Laboratory Medicine, 2017, 48(4):295-313.

[10] Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med., 2021, 10(11).

[11] Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia, 1993, 36:1119-25.

[12] Fayeza Karim1 QSA, Shamima Jahan3, Afruza Khanom4, Samira Haque5, Tania, yeasmin6 TS, Susmita Sinha. Coagulation Impairment in Type 2 Diabetes Mellitus. J Bangladesh Soc Physiol., 2015, 10(1):26-9.

[13] Toyosi AA, Oluwayemisi OH, Adenike DI, Kola OJ, Joyce O-AK. Assessment of coagulation and fibrinolytic factors among patients with type 2 diabetes mellitus in University of Ilorin Teaching Hospital, Ilorin, Nigeria. Annals of Clinical and Biomedical Research, 2021, 2(1).

[14] Pati S, Mohapatra M, Das S, Sabat SK. Coagulation Dynamics in Type 2 Diabetes Mellitus: Insights from PT and APTT Assessment. 2015.

[15] Sobczak AIS, Stewart AJ. Coagulatory Defects in Type-1 and Type-2 Diabetes. Int J Mol Sci., 2019, 20(24).

[16] Ephraim RK, Awuku YA, Adu P, Ampomah LT, Adoba P, Panford S, et al. High risk of coagulopathy among Type-2 Diabetes Mellitus clients at a municipal hospital in Ghana. Ghana Med J., 2017, 51(3):101-7.

[17] Ahmad S RH, Rahman WU, Mujahid M, Waleed HM. Assessment of Variations in PT, APTT and Platelet Count and Their Correlation with Glycated Hemoglobin in Type 2 Diabetes mellitus. RADS Journal of Biological Research & Applied Sciences, 2021, 12(2):108-12.

[18] Lemkes BA, Hermanides J, DeVries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? Journal of Thrombosis and Haemostasis, 2010, 8(8):1663-9.

[19] Prasad P GR, Kumar R. To Evaluate the Levels of PT, APTT & Fibrinogen Values in Patients with Type 2 Diabetes Mellitus. Journal of Indira Gandhi Institute of Medical Sciences, 2019, 5(1):31.

[20] Pandya M, Parmar C, Singh M. Study of prothrombin time and activated partial thromboplastin time in type ii diabetes mellitus. International Journal of Clinical and Diagnostic Pathology, 2020, 3(3):173-5.

[21] Ebrahim H, Asrie F, Getaneh Z. Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study. J Blood Med., 2021, 12:33-42.

[22] Dacie JV. Dacie and Lewis practical haematology. 11 ed. Elsevier Health Sciences; 2011.

[23] Kulkarni YL, Jadhav SS, Lad UP, Sable M, Ingole A, Nanaware N. A comparative study of coagulation profile of Type 2 diabetic individuals with healthy individuals. Int J Acad Med Pharm., 2023, 5(4):1510-3.

[24] Mohammed A. Assessment of some coagulation parameters (PT, APTT, INR, PLTS COUNT and PLT indices) in Sudanese Patients with Diabetic Type 2 January. European Academic Research, 2016:1570-85.

[25] Boshabor SO. Prothrombin Time, Activated Partial Thromboplastin Time and Platelet Count in Patients with Diabetes Mellitus. MINAR International Journal of Applied Sciences and Technology, 2022, 04(02):186-95.

[26] Ghosh K. Diabetes as a prothrombotic state. Mechanisms of Vascular Defects in Diabetes Mellitus, 2017:361-76.

[27] Jain A. Comparison of platelet indices in diabetics and healthy subjects. Journal of Advanced Medical and Dental Sciences Research, 2019, 7(11).

How to cite this paper

Yazal Abay, Melatwork Tibebu, Zemenu Tamir. Comparison of Coagulation Profile in Type 2 Diabetes Mellitus Patients at Durame General Hospital, South East Ethiopia: Comparative Cross-sectional Study. International Journal of Medicine Frontiers, 2024, 7(1), 35-42.

Copyright © 2022 Damray Co., Ltd. Privacy Policy | Terms and Conditions